Funding Opportunities

Looking to highlight a funding opportunity? Please send a brief description, link, and deadline to communications@massbio.org

State & Federal Programs

NIH Small Business Innovation Research (SBIR) and Small Business Technology Transfer  (SBTT) Grants

Innovative Molecular Analysis Technology Development for Cancer Research and Clinical Care (PAR-13-327)

The National Cancer Institute (NCI) announces the availability of a funding opportunity aimed at accelerating the development and commercialization of highly innovative technologies that improve molecular and/or cellular analysis of cancer with a significant likelihood for either overcoming persistent challenges or obstacles or opening entirely new fields for cancer research or clinical care. This Program Announcement complements the goals of the NCI's Innovative Molecular Analysis Technologies (IMAT) program by facilitating a path towards technology commercialization. Prior participation in the IMAT Program is not required for eligibility for this FOA. Applications are expected to indicate the significant attributes and advantages of the proposed technology over currently available technologies and conventional approaches. Click here to learn more.

Receipt Dates: May 28, 2014; November 4, 2014; May 27, 2015; November 4, 2015; May 27, 2016

Additional Opportunities

Michael J. Fox Foundation Grants

Deadline: October 28, 2015

The Michael J. Fox Foundation works tirelessly to accelerate promising research toward breakthroughs for Parkinson’s patients. While our strong emphasis is on funding translational and clinical research, we also support high-risk/high-reward discovery work. In addition to funding, awardees benefit from working with our internal research staff and broad network of scientific and industry advisors.

Core funding program opportunities include Target Advancement, Therapeutic Development, and Outcome Measures.

NORD 2015 Research Grants

Deadline: July 31, 2015

The NORD Research Grant Program provides seed-money grants to academic scientists for scientific and/or clinical research. The hope is that these studies will ultimately lead to new diagnostics, treatments, and/or cures for rare diseases. NORD’s program provides grants for the study of diseases for which there are few other sources of funding. Grants provided through the NORD program are made possible by donations from individuals and organizations to restricted research funds at NORD.

Illumina Accelerator

Deadline: July 2015

At Illumina, we’re committed to unlocking the power of the genome, but we know we can’t do it alone. The Illumina Accelerator is our way of accelerating innovation in the entrepreneurial community. With extensive mentorship, financial support, and access to sequencing systems, reagents, and lab space, we’ve created a dynamic genomic ecosystem to help startups launch. Together we’ll advance the solutions that will transform medicine and improve human health.

GSK Discovery Fast Track Challenge

Applications open March 23, 2015

Do you have a drug discovery concept? Are you a principal investigator affiliated with a U.S. or Canadian research institute, college or university? Are you excited about partnering with a leading pharmaceutical company to translate your novel science into a new medicine?  If so, the Discovery Fast Track Challenge is for you.

The Michael J. Fox Foundation Rapid Response Innovation Awards

Deadline: No deadline; applications accepted anytime

One-year grants to jump start new ideas in PD research. The Rapid Response Innovation Awards (RRIA) program supports high-risk, high-reward projects with little-to-no existing preliminary data, but with potential to significantly impact our understanding of Parkinson’s disease.  Moreover, this program is well-suited for early exploratory studies that may open the field up to new targets or pathways that may ultimately feed the early drug development pipeline for a treatment of PD.

Delivering Scientific Innovation for Autism LLC (DELSIA) Product Development Funding

There is no deadline to apply; submit an Expressions of Interest here.

DELSIA is an independent nonprofit venture philanthropy affiliate of the autism research and advocacy foundation Autism Speaks. DELSIA provides funds to for-profit partners to advance the development of products that address unmet medical and behavioral health needs of the autism community. It was created as an innovative funding vehicle with the goal of improving outcomes for individuals with autism spectrum disorder (ASD). DELSIA aims to do this by ensuring that scientific breakthroughs and technological advances are developed into products that improve health and quality of life for individuals with autism and their families. Our purpose is to transform lives by serving as a catalyst to facilitate and accelerate the delivery and availability of impactful products.

 

Evaluate